EMVision

Executive Summary

EMVision is an Australian med-tech company developing a portable, non-ionising brain scanner that leverages electromagnetic imaging and artificial intelligence to enable rapid, bedside diagnosis and monitoring of stroke. The device aims to address critical limitations of current stroke diagnostics, which rely on fixed CT or MRI scanners that are costly, bulky, and often inaccessible in pre-hospital settings. By providing a compact, safe, and cost-effective alternative, EMVision’s technology has the potential to significantly shorten the time-to-treatment for stroke patients, improve outcomes, and expand access to neuro-diagnostics in remote or resource-limited environments. The company is currently in the preclinical stage, with a focus on validating its imaging platform and AI algorithms through benchtop and animal studies. EMVision's progress to date includes successful proof-of-concept demonstrations and ongoing development efforts to refine the device for human use. As a private company with a small team of 10-50 employees, it operates in a highly competitive landscape that includes other portable neuro-imaging solutions. However, its unique electromagnetic approach offers differentiation from ultrasound- or microwave-based alternatives. Upcoming catalysts for EMVision include the initiation of first-in-human clinical trials, potential recognition through FDA breakthrough device designation, and strategic partnerships with healthcare institutions to support clinical development and eventual commercialisation. The company’s ability to secure additional funding and meet regulatory milestones will be critical to its near-term success.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation60% success
• Q2 2027FDA breakthrough device designation50% success
• Q3 2026Partnership with major stroke center for clinical validation40% success